Savara Inc. (SVRA)
NASDAQ: SVRA · Real-Time Price · USD
5.61
+0.01 (0.18%)
Aug 26, 2026, 4:00 PM EDT - Market closed
Savara Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
70
Market Cap
1.43B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 257.00K | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | 400.00K | 346.00K | 640.74% |
| Dec 31, 2015 | 54.00K | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | 300.00K | -200.00K | -40.00% |
| Dec 31, 2008 | 500.00K | - | - |
| Dec 31, 2007 | 500.00K | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
SVRA News
- 2 days ago - Savara announces presentations of Results from Phase 3 trial of Molgramostim - TheFly
- 2 days ago - Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026 - Business Wire
- 6 days ago - Savara Announces New Employment Inducement Grant - Business Wire
- 15 days ago - Savara reports Q2 EPS (16c), consensus (15c) - TheFly
- 15 days ago - Savara Reports Second Quarter 2026 Financial Results and Provides Business Update - Business Wire
- 15 days ago - Savara Quarterly report: Q2 2026 - Filings
- 15 days ago - Savara Earnings release: Q2 2026 - Filings
- 15 days ago - Savara Slides: Corporate presentation - Filings